Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash-to-Debt 0.15
AMEX:CVM's Cash-to-Debt is ranked lower than
94% of the 1046 Companies
in the Global Biotechnology industry.

( Industry Median: 55.72 vs. AMEX:CVM: 0.15 )
Ranked among companies with meaningful Cash-to-Debt only.
AMEX:CVM' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.15  Med: 1315.87 Max: No Debt
Current: 0.15
0.15
No Debt
Equity-to-Asset -0.22
AMEX:CVM's Equity-to-Asset is ranked lower than
94% of the 767 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. AMEX:CVM: -0.22 )
Ranked among companies with meaningful Equity-to-Asset only.
AMEX:CVM' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.63  Med: 0.68 Max: 0.99
Current: -0.22
-0.63
0.99
Debt-to-Equity -2.92
AMEX:CVM's Debt-to-Equity is ranked lower than
99.99% of the 494 Companies
in the Global Biotechnology industry.

( Industry Median: 0.26 vs. AMEX:CVM: -2.92 )
Ranked among companies with meaningful Debt-to-Equity only.
AMEX:CVM' s Debt-to-Equity Range Over the Past 10 Years
Min: -19.16  Med: 0.06 Max: 1.67
Current: -2.92
-19.16
1.67
Debt-to-EBITDA -0.68
AMEX:CVM's Debt-to-EBITDA is ranked lower than
99.99% of the 214 Companies
in the Global Biotechnology industry.

( Industry Median: 1.94 vs. AMEX:CVM: -0.68 )
Ranked among companies with meaningful Debt-to-EBITDA only.
AMEX:CVM' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.69  Med: -0.1 Max: 0.1
Current: -0.68
-0.69
0.1
Piotroski F-Score: 2
Altman Z-Score: -22.03
Beneish M-Score: 13.46
WACC vs ROIC
12.20%
-1549.29%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -12916.36
AMEX:CVM's Operating Margin % is ranked lower than
93% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -105.96 vs. AMEX:CVM: -12916.36 )
Ranked among companies with meaningful Operating Margin % only.
AMEX:CVM' s Operating Margin % Range Over the Past 10 Years
Min: -190240  Med: -10926.73 Max: -1881.38
Current: -12916.36
-190240
-1881.38
Net Margin % -14589.09
AMEX:CVM's Net Margin % is ranked lower than
96% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -92.13 vs. AMEX:CVM: -14589.09 )
Ranked among companies with meaningful Net Margin % only.
AMEX:CVM' s Net Margin % Range Over the Past 10 Years
Min: -154060  Med: -5900.65 Max: 6851.63
Current: -14589.09
-154060
6851.63
ROA % -166.73
AMEX:CVM's ROA % is ranked lower than
90% of the 1052 Companies
in the Global Biotechnology industry.

( Industry Median: -32.93 vs. AMEX:CVM: -166.73 )
Ranked among companies with meaningful ROA % only.
AMEX:CVM' s ROA % Range Over the Past 10 Years
Min: -181.93  Med: -78.7 Max: 25.01
Current: -166.73
-181.93
25.01
ROC (Joel Greenblatt) % -312.58
AMEX:CVM's ROC (Joel Greenblatt) % is ranked higher than
60% of the 1014 Companies
in the Global Biotechnology industry.

( Industry Median: -432.52 vs. AMEX:CVM: -312.58 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
AMEX:CVM' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2583.59  Med: -595.35 Max: 687.95
Current: -312.58
-2583.59
687.95
3-Year Revenue Growth Rate -56.80
AMEX:CVM's 3-Year Revenue Growth Rate is ranked lower than
87% of the 592 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. AMEX:CVM: -56.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
AMEX:CVM' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -77.1  Med: -21.4 Max: 370.5
Current: -56.8
-77.1
370.5
3-Year EBITDA Growth Rate -37.20
AMEX:CVM's 3-Year EBITDA Growth Rate is ranked lower than
88% of the 701 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. AMEX:CVM: -37.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
AMEX:CVM' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -51.6  Med: -10.6 Max: 60.4
Current: -37.2
-51.6
60.4
3-Year EPS without NRI Growth Rate -46.10
AMEX:CVM's 3-Year EPS without NRI Growth Rate is ranked lower than
91% of the 683 Companies
in the Global Biotechnology industry.

( Industry Median: -1.10 vs. AMEX:CVM: -46.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
AMEX:CVM' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -51  Med: -11.7 Max: 41.3
Current: -46.1
-51
41.3
GuruFocus has detected 3 Warning Signs with CEL-SCI Corp AMEX:CVM.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» AMEX:CVM's 30-Y Financials

Financials (Next Earnings Date: 2018-05-10)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

CVM Guru Trades in

Q4 2016

CVM Guru Trades in Q4 2016

Jim Simons 689,400 sh (New)
» More
Q1 2017

CVM Guru Trades in Q1 2017

Jim Simons 42,600 sh (-93.82%)
» More
Q2 2017

CVM Guru Trades in Q2 2017

Jim Simons Sold Out
» More
» Details

Insider Trades

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:TSXV:BTI, NAS:TTNP, LSE:REDX, OTCPK:CRYO, NAS:CUR, NAS:DMPI, BOM:500259, NAS:ONS, ASX:IMU, TSE:6190, ASX:PAR, OTCPK:RGRX, MIC:LIFE, NAS:ALT, OSTO:ISR, OSTO:PROMO, ASX:OCC, AMEX:CRMD, NAS:VICL, TSX:IPCI » details
Traded in other countries:LSRM.Germany,
Headquarter Location:USA
CEL-SCI Corp is a biotechnology company. It is engaged in the research and development directed at improving the treatment of cancer and other diseases by utilizing the immune system, the body's natural defense system.

CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The company is focused on activating the immune system to fight cancer and infectious diseases. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), an investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.

Ratios

vs
industry
vs
history
PS Ratio 108.77
AMEX:CVM's PS Ratio is ranked lower than
90% of the 731 Companies
in the Global Biotechnology industry.

( Industry Median: 11.11 vs. AMEX:CVM: 108.77 )
Ranked among companies with meaningful PS Ratio only.
AMEX:CVM' s PS Ratio Range Over the Past 10 Years
Min: 30.55  Med: 254.67 Max: 12031.67
Current: 108.77
30.55
12031.67
EV-to-EBIT -1.92
AMEX:CVM's EV-to-EBIT is ranked lower than
99.99% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.83 vs. AMEX:CVM: -1.92 )
Ranked among companies with meaningful EV-to-EBIT only.
AMEX:CVM' s EV-to-EBIT Range Over the Past 10 Years
Min: -18.9  Med: -3.5 Max: 29.5
Current: -1.92
-18.9
29.5
EV-to-EBITDA -1.98
AMEX:CVM's EV-to-EBITDA is ranked lower than
99.99% of the 285 Companies
in the Global Biotechnology industry.

( Industry Median: 20.69 vs. AMEX:CVM: -1.98 )
Ranked among companies with meaningful EV-to-EBITDA only.
AMEX:CVM' s EV-to-EBITDA Range Over the Past 10 Years
Min: -19.9  Med: -3.7 Max: 28.2
Current: -1.98
-19.9
28.2
EV-to-Revenue 247.86
AMEX:CVM's EV-to-Revenue is ranked lower than
91% of the 776 Companies
in the Global Biotechnology industry.

( Industry Median: 12.21 vs. AMEX:CVM: 247.86 )
Ranked among companies with meaningful EV-to-Revenue only.
AMEX:CVM' s EV-to-Revenue Range Over the Past 10 Years
Min: 27.9  Med: 271 Max: 11287.5
Current: 247.86
27.9
11287.5
Current Ratio 0.34
AMEX:CVM's Current Ratio is ranked lower than
96% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. AMEX:CVM: 0.34 )
Ranked among companies with meaningful Current Ratio only.
AMEX:CVM' s Current Ratio Range Over the Past 10 Years
Min: 0.17  Med: 5.45 Max: 160
Current: 0.34
0.17
160
Quick Ratio 0.28
AMEX:CVM's Quick Ratio is ranked lower than
95% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 3.86 vs. AMEX:CVM: 0.28 )
Ranked among companies with meaningful Quick Ratio only.
AMEX:CVM' s Quick Ratio Range Over the Past 10 Years
Min: 0.04  Med: 4.98 Max: 160
Current: 0.28
0.04
160
Days Sales Outstanding 106.18
AMEX:CVM's Days Sales Outstanding is ranked higher than
98% of the 650 Companies
in the Global Biotechnology industry.

( Industry Median: 65.03 vs. AMEX:CVM: 106.18 )
Ranked among companies with meaningful Days Sales Outstanding only.
AMEX:CVM' s Days Sales Outstanding Range Over the Past 10 Years
Min: 48.33  Med: 174.48 Max: 1153.19
Current: 106.18
48.33
1153.19

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -53.70
AMEX:CVM's 3-Year Average Share Buyback Ratio is ranked lower than
84% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. AMEX:CVM: -53.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AMEX:CVM' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -71.4  Med: -26 Max: 0
Current: -53.7
-71.4
0

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.43
AMEX:CVM's Price-to-Median-PS-Value is ranked higher than
62% of the 629 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. AMEX:CVM: 0.43 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
AMEX:CVM' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.05  Med: 0.51 Max: 34.93
Current: 0.43
0.05
34.93
Earnings Yield (Greenblatt) % -52.03
AMEX:CVM's Earnings Yield (Greenblatt) % is ranked lower than
79% of the 1050 Companies
in the Global Biotechnology industry.

( Industry Median: -7.37 vs. AMEX:CVM: -52.03 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AMEX:CVM' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -297.1  Med: -25 Max: 13.9
Current: -52.03
-297.1
13.9

More Statistics

Revenue (TTM) (Mil) $0.17
EPS (TTM) $ -2.88
Beta0.22
Short Percentage of Float9.17%
52-Week Range $1.46 - 3.92
Shares Outstanding (Mil)16.60

Analyst Estimate

Sep18
Revenue (Mil $)
EBIT (Mil $)
EBITDA (Mil $)
EPS ($) -1.04
EPS without NRI ($) -1.04
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 22
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}